<DOC>
	<DOCNO>NCT00282672</DOCNO>
	<brief_summary>The purpose study determine intervention 510 ( k ) -cleared endoscopically-guided ( Halo Ablation system ) , ablation system plus anti-secretory therapy well anti-secretory therapy alone clear Barrett 's Esophagus .</brief_summary>
	<brief_title>Ablation Intestinal Metaplasia Containing Dysplasia</brief_title>
	<detailed_description>Barrett 's esophagus intestinal metaplasia ( IM ) change epithelial lining esophagus . Barrett 's esophagus develop result chronic exposure esophagus refluxed stomach acid enzyme , well bile , result recurrent mucosal injury . Injury accompany inflammation , ultimately , cellular change ( metaplasia ) specialize columnar epithelium ( Spechler SJ . Barrett 's Esophagus . N Engl J Med 2002 ; 346 ( 11 ) :836-842 . ) Patients diagnosis Barrett 's esophagus typically undergo surveillance endoscopy every 1-3 year multiple biopsy specimen obtain facilitate early detection progression IM dysplasia ( severe precancerous change ) adenocarcinoma . ( Sampliner RE . Updated guideline diagnosis , surveillance , therapy Barrett 's esophagus . Am J Gastro 2002 ; 97:1888-1895 . ) Progression IM low-grade dysplasia ( LGD ) indicate cell exhibit `` cancer-like '' architecture , thus warrant accelerate surveillance endoscopy biopsy program every 6 month rather every 1-3 year indicate non-dysplastic IM . Progression high-grade dysplasia ( HGD ) indicate cell even `` cancer-like '' , thus warrant even high frequency surveillance endoscopy biopsy program ( every 3 month ) . Many HGD patient may undergo photodynamic therapy ( PDT ) surgical esophagectomy , rather remain frequent surveillance program . This aggressive therapy warrant high rate progression HGD adenocarcinoma . Esophageal adenocarcinoma commonly occur insidious progression IM LGD HGD . Therefore , surveillance increase upon diagnosis worsen grade dysplasia . The incidence esophageal adenocarcinoma rapidly increase middle-aged elderly demographic sub-groups expand ( Peters JH , Hagen JA , DeMeester SR. Barrett 's Esophagus . J Gastrointest Surg 2004 ; 8 ( 1 ) :1-17 . ) In 2004 , American Cancer Society report 14,250 new case esophageal cancer , 13,300 death attributable esophageal cancer ( www.cancer.org ) . The U.S. National Cancer Institute Surveillance , Epidemiology End Results Program report increase incidence esophageal adenocarcinoma great cancer United States ( www.cancer.gov ) . Elimination diseased epithelium contain IM dysplasia intuitively favorable step patient diagnosis . In disease state , colon polyp premalignant skin lesion , removal premalignant tissue result reduction risk ultimately develop cancer . This logical conclusion consider premalignant lesion Barrett 's esophagus ( particularly Barrett 's esophagus dysplasia ) , `` tissue risk '' completely remove ablation . This premise test Barrett 's dysplasia population photoablative trial use PDT patient HGD , PDT impart 50 % reduction risk control development adenocarcinoma ( Overholt BF , Panjehpour M , Haydek JM . Photodynamic therapy Barrett 's esophagus : follow-up . Gastrointest Endosc 1999 ; 49 ( 1 ) :1-7 . ) The AIM Dysplasia Trial primary endpoint removal dysplasia IM , rather detection difference progression adenocarcinoma high grade dysplasia .</detailed_description>
	<mesh_term>Barrett Esophagus</mesh_term>
	<mesh_term>Metaplasia</mesh_term>
	<mesh_term>Proton Pump Inhibitors</mesh_term>
	<criteria>1.Subject 1880 year age , inclusive . 2.Subject documented diagnosis IM , maximum endoscopic length 8 cm ( measure endoscopically TGF proximal extent IM ; i.e . TGFTIM contain dysplasia follow : 1 . For LGD : i.LGD document biopsy within previous 12 month enrollment subject PPI therapy . ii.Histology slide review central pathology service trial confirm LGD first confirmatory central pathology review , necessary , confirm LGD tiebreaker review second pathologist . 2 . For HGD : i.Regular , nonnodular , nonulcerated mucosa . ii.HGD document biopsy within previous 6 month enrollment . iii.Histology slide review central pathology service Trial confirm HGD first confirmatory review , necessary , confirm HGD tiebreaker review second pathologist . iv.Baseline EUS within previous 12 month ; 1.Catheterbased EUS excludes suspicious thicken Barrett 's area , suspicious area find , prompt stack biopsy thicken area , result render subject ineligible enrollment . 3.For subject EMR history , document diagnosis IM dysplasia meet criterion # 2 biopsy collect either EMR procedure EMR procedure EMR site . 4.Subject able take oral proton pump inhibitor medication . 5.Subject able discontinue aspirin and/or nonsteroidal antiinflammatory medication 7 day ablation procedure . 6.For female subject childbearing potential , negative pregnancy test within 2 week randomization . 7.Subject eligible treatment followup endoscopy biopsy require Protocol . 8.Subject willing provide write , inform consent participate clinical study understand responsibility trial participation . 1.The subject pregnant planning pregnancy study period . 2.Esophageal stricture prevent passage endoscope catheter . 3.Active esophagitis describe erosion ulceration encompass 10 % distal esophagus . 4.Any history malignancy esophagus . 5.Prior radiation therapy esophagus , except head neck region radiation therapy . 6.Any previous ablative therapy within esophagus ( PDT , MPEC , APC , laser treatment , ) . 7.History EMR meet follow criterion : a.EMR perform less 8 week prior randomization endoscopy encounter b.EMR perform wide field manner ( encompass 90 degree area esophagus . 8.Any previous esophageal surgery , include except fundoplication without complication ( i.e . slippage , dysphagia , etc ) . 9.Evidence esophageal varix treatment endoscopy . 10.Report uncontrolled coagulopathy international normalize ratio ( INR ) &gt; 1.3 platelet count &lt; 75,000 platelet per ÂµL 11.Subject lifeexpectancy less two year due underlie medical condition . 12.Subject known history unresolved drug alcohol dependency would limit ability comprehend follow instruction relate informed consent , posttreatment instruction , followup guideline . 13.Subject implantable pace device ( example ; AICD , neurostimulator , cardiac pacemaker ) receive clearance enrollment study specialist responsible pacing device . 14.The subject currently enrol investigational drug device trial clinically interfere AIM Dysplasia Trial endpoint . 15.Subject suffers psychiatric illness deem investigator inability comply protocol . For 5 year extension , patient must have:1 . Enrolled B204 protocol . 2 . Completed 1 year followup . 3 . Completed 2 year followup .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Barrett 's Esophagus</keyword>
	<keyword>Dysplasia</keyword>
	<keyword>Radiofrequency Ablation</keyword>
</DOC>